WorldCat Identities

Miele, Lucio

Overview
Works: 19 works in 29 publications in 2 languages and 513 library holdings
Roles: Instrumentalist, Editor, Contributor, Other
Publication Timeline
.
Most widely held works by Lucio Miele
Intersezioni( )

2 editions published in 2017 in Italian and held by 259 WorldCat member libraries worldwide

Targeting notch in cancer : from the fruit fly to the clinic( )

8 editions published in 2018 in English and Undetermined and held by 221 WorldCat member libraries worldwide

The serendipitously discovered link between developmental biology and cancer, touched of an explosion of discoveries on the role of Notch in human malignancies, including every aspect of cancer biology, from control of differentiation, proliferation and apoptosis in transformed cells to angiogenesis, tumor-stroma interaction and anti-cancer immune responses. A number of observations have revealed that Notch even plays a role in the renewal of cancer stem cells and tumor initiating cells, which are thought to be a major cause of resistance to treatment. Targeting Notch in Cancer will provide researchers, oncologists, pharmacologists and students with a detailed understanding of the intricate cross-talk between Notch and other pathways of therapeutic interest so to better design rational drug combinations for specific diseases and disease subsets. Divided into two parts, Part I describes in detail what we know about the genetics, molecular biology, biochemistry and structural biology of Notch, as well as the role of Notch in such processes as angiogenesis and immune surveillance. Without insights gained from these basic studies, rational targeting of Notch in human disease would be impossible. Part II describes the role of Notch and ongoing experimental therapeutic efforts in the most important subtypes of human cancers, organized in a clinically oriented fashion by organs and systems affected
Integrating GWAS with gene expression data to dissect the genetic architecture of triple-negative breast cancer by Chindo Hicks( )

2 editions published in 2011 in English and held by 4 WorldCat member libraries worldwide

Notch-1-PTEN-ERK1/2 signaling axis promotes HER2+ breast cancer cell proliferation and stem cell survival by Andrew Baker( )

1 edition published in 2018 in English and held by 2 WorldCat member libraries worldwide

Enhancer of zeste homolog 2 (EZH2) in pediatric soft tissue sarcomas: first implications by Roberta Ciarapica( )

1 edition published in 2011 in English and held by 2 WorldCat member libraries worldwide

Boronic prodrug of 4-hydroxytamoxifen is more efficacious than tamoxifen with enhanced bioavailability independent of CYP2D6 status by Qiu Zhong( )

1 edition published in 2015 in English and held by 2 WorldCat member libraries worldwide

Notch signals in the endothelium and cancer "stem-like" cells: opportunities for cancer therapy by Jian-Wei Gu( )

1 edition published in 2012 in English and held by 2 WorldCat member libraries worldwide

ARG2 and NOS2 as predictive biomarkers in renal cell carcinoma by Virginia White( )

1 edition published in 2015 in English and held by 2 WorldCat member libraries worldwide

Epoxyazadiradione suppresses breast tumor growth through mitochondrial depolarization and caspase-dependent apoptosis by targeting PI3K/Akt pathway by Dhiraj Kumar( )

1 edition published in 2018 in English and held by 2 WorldCat member libraries worldwide

Drug resistance profiling of a new triple negative breast cancer patient-derived xenograft model by Margarite D Matossian( )

1 edition published in 2019 in English and held by 2 WorldCat member libraries worldwide

Distinct gene expression profiles associated with Notch ligands Delta-like 4 and Jagged1 in plaque material from peripheral artery disease patients: a pilot study by Giorgio Aquila( )

1 edition published in 2017 in English and held by 2 WorldCat member libraries worldwide

A novel patient-derived xenograft model for claudin-low triple-negative breast cancer by Margarite D Matossian( )

1 edition published in 2018 in English and held by 2 WorldCat member libraries worldwide

Notch signaling in pediatric soft tissue sarcomas by Rossella Rota( )

1 edition published in 2012 in English and held by 2 WorldCat member libraries worldwide

Gamma-Secretase and Notch Signaling: Novel Therapeutic Targets In Breast Cancer( Book )

2 editions published in 2005 in English and held by 2 WorldCat member libraries worldwide

We are on track and have made significant progress in our project. We have determined that, as predicted by our hypothesis, LY411,575 is a Notch inhibitor which synergizes with paclitaxel. We have discovered an additional synergism with tamoxifen. We have made several key mechanistic observations on how Notch inhibition causes growth arrest and death in breast cancer cells regardless of ER status. We have determined the optimal conditions for in vivo administration of LY411,575 and we have obtained preliminary xenograft data which confirm significant anti- tumor activity at safe doses of this compound. We expect to complete our study and publish its results within the expected 3-year time frame. We expect our results will not only demonstrate that a GSI/paclitaxel regimen is a promising treatment for ER negative breast cancer, but also that a GSI/tamoxifen combination could be just as promising in ER positive cancers. Based on these data, we will propose 2 phase 1 clinical trials of this compound or its close derivative(s) produced by Eli Lilly in the neo-adjuvant setting at first. In conclusion, we expect that the completion of this project will directly lead to the identification of a new broadly active class of agents for the treatment of breast cancer, the clarification of their primary mode of action and the suggestion of possible combination therapeutic regimens
NOTCH-1 and NOTCH-4 are novel gene targets of PEA3 in breast cancer: novel therapeutic implications by Anthony G Clementz( )

1 edition published in 2011 in English and held by 2 WorldCat member libraries worldwide

Retraction notice to "Notch-1 induces Epithelial-mesenchymal transition consistent with cancer stem cell phenotype in pancreatic cancer cells."( )

1 edition published in 2018 in English and held by 1 WorldCat member library worldwide

Abstract : This article has been retracted: please see Elsevier Policy on Article Withdrawal (http://www.elsevier.com/locate/withdrawalpolicy). This article has been retracted at the request of the Editor in Chief. An investigation by Wayne State University identified a discrepancy between the data reported in Figures1B, 2B and 3C and the original collected data. The investigation committee concluded that this undermined the scientific basis of the publication, that no credible replacement data were available, and advised that the publication should be retracted
The sphingosine kinase 2 inhibitor ABC294640 displays anti-non-small cell lung cancer activities in vitro and in vivo( )

1 edition published in 2018 in English and held by 1 WorldCat member library worldwide

Abstract : Non-small cell lung cancer (NSCLC) accounts for about 85-90% of lung cancer cases, and is the number one killer among cancers in the United States. The majorities of lung cancer patients do not respond well to conventional chemo- and/or radio-therapeutic regimens, and have a dismal 5-year survival rate of <"5%. The recent introduction of targeted therapy and immunotherapy gives new hopes to NSCLC patients, but even with these agents, not all patients respond, and responses are rarely complete. Thus, there is still an urgent need to identify new therapeutic targets in NSCLC and develop novel anti-cancer agents. Sphingosine kinase 2 (SphK2) is one of the key enzymes in sphingolipid metabolism. SphK2 expression predicts poor survival in NSCLC patients, and is associated with Gefitinib-resistance. In this study, the anti-NSCLC activities of ABC294640, the only first-in-class orally available inhibitor of SphK2, were explored. The results obtained indicate that ABC294640 treatment causes significant NSCLC cell apoptosis, cell cycle arrest and suppression of tumor growth in vitro and in vivo . Moreover, lipidomics analyses revealed the complete signature of ceramide and dihydro(dh)-ceramide species in the NSCLC cell-lines with or without ABC294640 treatment. These findings indicate that sphingolipid metabolism targeted therapy may be developed as a promising strategy against NSCLC. Abstract : What's new? Therapeutic resistance and poor survival in non-small cell lung cancer (NSCLC) are associated with expression of sphingosine kinase 2 (SphK2), an enzyme involved in sphingolipid metabolism. Anti-tumor activity via SphK2 inhibition with the small molecule ABC294640 is possible, though data are limited for NSCLC. Here, in NSCLC cell lines and a mouse xenograft model, ABC294640 treatment was associated with tumor cell apoptosis, cell cycle arrest and reduced tumor growth. In NSCLC cells, ABC294640 treatment resulted in increased levels of bioactive sphingolipids, specifically ceramides and dihydro(dh)-ceramides. The data indicate that ABC294640 exerts significant anti-NSCLC activity in vitro and in vivo
Uteroglobin, a possible ligand of the lipoxin receptor inhibits serum amyloid A-driven inflammation( )

1 edition published in 2014 in English and held by 1 WorldCat member library worldwide

 
moreShow More Titles
fewerShow Fewer Titles
Audience Level
0
Audience Level
1
  Kids General Special  
Audience level: 0.45 (from 0.31 for Integratin ... to 0.97 for Gamma-Secr ...)

WorldCat IdentitiesRelated Identities
Alternative Names
Lucio Miele onderzoeker

Languages